Antibiotic prophylaxis for selected gynecologic surgeries by Morrill, Michelle Y. et al.
International Journal of Gynecology and Obstetrics 120 (2013) 10–15
Contents lists available at SciVerse ScienceDirect
International Journal of Gynecology and Obstetrics
j ourna l homepage: www.e lsev ie r .com/ locate / i jgoREVIEW ARTICLE
Antibiotic prophylaxis for selected gynecologic surgeries☆
Michelle Y. Morrill a, Megan O. Schimpf b,⁎, Husam Abed c, Cassandra Carberry d, Rebecca U. Margulies e,
Amanda B. White f, Lior Lowenstein g, Renée M. Ward h, Ethan M. Balk i, Katrin Uhlig i, Vivian W. Sung d;
for the Society of Gynecologic Surgeons Systematic Review Group
a Department of Obstetrics and Gynecology, Kaiser Medical Center San Francisco, San Francisco, USA
b Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, USA
c Department of Obstetrics and Gynecology, Henry Ford Health System, Detroit, USA
d Department of Obstetrics and Gynecology, Women and Infants Hospital of Rhode Island/Brown Medical School, Providence, USA
e Department of Obstetrics and Gynecology, Kaiser Medical Center Oakland, Oakland, USA
f Department of Obstetrics and Gynecology, University of Texas Southwestern at Seton Healthcare Family, Austin, USA
g Urogynecology Service, Rambam Health Care Campus, Technion Faculty of Medicine, Haifa, Israel
h Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, USA
i Department of Medicine, Tufts Medical Center, Boston, USA☆ This review was presented at the 37th Annual Scien
Gynecologic Surgeons, San Antonio, Texas, on April 11,
⁎ Corresponding author at: University of Michigan, L4
Center Drive, Ann Arbor, MI 48109, USA. Tel.: +1 734 64
E-mail address: mschimpf@umich.edu (M.O. Schimp
0020-7292/$ – see front matter © 2012 International Fed
http://dx.doi.org/10.1016/j.ijgo.2012.06.023a b s t r a c ta r t i c l e i n f oArticle history:
Received 30 April 2012
Received in revised form 28 June 2012





Background: Antibiotic prophylaxis for surgery is commonly used and is recommended by multiple or-
ganizations. Objective: To critically review gynecology-specific data regarding surgical antibiotic prophy-
laxis in selected benign gynecologic surgeries. Search strategy: MEDLINE and Cochrane databases were
searched from inception to July 2010. Selection criteria: Randomized controlled trials of benign vaginal,
cervical, transcervical, abdominal, or laparoscopic procedures other than hysterectomy comparing pro-
phylactic antibiotic use with placebo or with another antibiotic. Outcomes of interest were postoperative
infections, additional treatments, and adverse events. Data collection and analysis: In total, 19 trials met the
inclusion criteria. Studies were individually assessed for methodologic quality, then grouped by procedure
and evaluated for evidence quality. Main results: There was no difference in infectious outcome for loop
electrosurgical excision, hysteroscopic ablation, or laparoscopy, although evidence quality was poor. Fair
evidence supports antibiotic prophylaxis for suction curettage or laparotomy. There were insufficient
data regarding vaginal surgery prophylaxis. Conclusion: Antibiotic prophylaxis may be beneficial in
first-trimester suction curettage and laparotomy. No advantage was found for loop electrosurgical exci-
sion, hysteroscopy, or laparoscopic gynecologic surgery. Newer procedures and vaginal surgery lack
research and merit study.
© 2012 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.1. Introduction
Antibiotic prophylaxis for gynecologic surgery has become a wide-
ly accepted practice for reducing post-surgical complications such as
wound infections, vaginal cuff cellulitis, endometritis, urinary tract
infections (UTIs), and foreign-body infections. Intravenous medica-
tions given shortly before the start of surgery are recommended by
many hospitals, accrediting bodies, and national organizations. In-
deed, some complications, including UTIs, are being evaluated as
markers of quality and qualifiers for payment by insurers and other
governing bodies. Although prophylaxis is generally thought to betific Meeting of the Society of
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eration of Gynecology and Obstetrics.safe, unnecessary administration of antibiotics is undesirable because
it can result in antibiotic-resistant bacteria, unnecessary cost, adverse
reactions, and changes in natural flora [1].
As with any widely accepted practice, antibiotic prophylaxis bears
periodic scrutiny regarding the supporting evidence. The collective
guidelines available from the American College of Obstetricians and
Gynecologists (ACOG) [1] and the Surgical Infection Prevention Pro-
ject [2] do not necessarily provide uniform guidance to gynecologic
surgeons. A recent study indicated that compliance with prophylaxis
is incomplete and that local hospital-based guidelines may supersede
national guidelines [3]. Furthermore, with the advent of many new
surgeries, including minimally invasive procedures and mesh-based
surgery, data regarding prophylaxis for these procedures are not
well known and merit review.
The aim of the present study was to review the gynecology-
specific literature regarding antibiotic prophylaxis to determine the
quality of evidence underpinning current guidelines and to identify
areas for future study.Published by Elsevier Ireland Ltd. All rights reserved.
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The Society of Gynecologic Surgeons Systematic Review Group
(SGS-SRG) comprises practicing gynecologists and is assisted by
experts in systematic-review methodology. The antibiotic prophy-
laxis subgroup of the SGS-SRG created a protocol defining popula-
tion, interventions, comparators, and outcomes (PICO) to evaluate
antibiotic prophylaxis in non-hysterectomy gynecologic surgery
for benign conditions.
The population of interest was women undergoing vaginal, cervi-
cal, transcervical, abdominal, or laparoscopic benign gynecologic pro-
cedures excluding hysterectomy. The focus was on non-hysterectomy
procedures in order to avoid redundancy with an ongoing (as of
September 2012) systematic review by the Cochrane Collaboration
regarding prophylactic antibiotics for hysterectomy [4]. The interven-
tion was prophylactic antibiotic use compared with placebo or with
another antibiotic, of any dose, route of administration, or periopera-
tive timing. The outcomes of interest were clinically diagnosed or
treated postoperative surgical and non-surgical site infections and
adverse effects related to antibiotic use.
MEDLINE and the Cochrane Central Register of Controlled Trials
were searched from inception to July 16, 2010, for English-language
randomized controlled trials (RCTs). Search terms were determined
by group discussion and review of literature terminology, and includ-
ed “antibiotic prophylaxis,” “premedication,” and specific gynecologic
procedures. A list of the medical subject headings used is available on
request. Additional studies were identified from references of rele-
vant review articles. Unpublished articles or abstracts were not iden-
tified, and study authors were not contacted.
The yield of citations was screened, and potentially eligible arti-
cles were then reviewed in full text to determine whether inclusion
criteria were met. Data extraction of included articles was
performed in duplicate. The extraction form was piloted by sub-
group members before it was finalized. Extraction forms identified
the PICO variables and study design details such as characteristics
and discrepancies between groups, outcome definition, whether
power was calculated and met, and applicability of study findings.
Using a system modified from the Agency for Healthcare Research
and Quality [5], extractors graded the quality of each study as
good, fair, or poor, based on the likelihood of bias. Bias was
assessed for factors including funding, blinding of patients/investi-
gators, and loss of patients to follow-up. The best measurement of
postoperative infection—the primary outcome for the present
review—was identified in each study. The quality of an outcome
within a study was assessed and the overall study quality down-
graded if there were limitations specific to the outcome. Discrepan-
cies between extractors were resolved by discussion among all
subgroup members.
Evidence profiles for each procedure were created and the quality
of the evidence was graded following the GRADE approach, based
on individual study quality, consistency across studies, directness
(applicability/generalizability of the population and intervention),
and sparseness of data [6]. The net effect of antibiotic prophylaxis
was classified as favoring antibiotic use, failing to show a difference
between groups, or favoring the alternative (including placebo).
Decisions were made by discussion and consensus among all members
for specific topic subgroups.3. Results
The literature search identified 2525 citations, of which 2301 were
excluded based on title and abstract. Of the 224 full-text articles
reviewed, 205 were excluded for not meeting PICO criteria (Fig. 1).
Nineteen articles were included in the present systematic review
(Supplementary Material S1).3.1. Cervical surgery (loop electrosurgical excision procedure)
Two studies on cervical surgery—specifically, loop electrosurgical
excision procedure (LEEP)—met the inclusion criteria [7,8]. Both
were graded fair quality. Foden-Shroff et al. [7] compared oral
ofloxacin for 5 days after LEEP with placebo in an evenly divided
group of 500 women. Need for antibiotics to treat vaginal discharge
in the 2 weeks after surgery was used as an indicator of infection.
Women were queried on medication adverse effects. The study was
limited by poor follow-up and lack of demographic information.
Also, the definition of infection was not specific because discharge
alone does not necessarily indicate infection. There was no difference
in infection rate between the groups (13.2% ofloxacin vs 10.3% place-
bo; P=0.39); placebo was favored owing to adverse effects (11.6%
ofloxacin vs 7.4% placebo; P=0.21).
The other LEEP study, performed in Hong Kong, compared a group
using a vaginal pessary containing 100 mg of tetracycline and 50 mg
of amphotericin B—placed twice daily for 14 days, starting on the day
of the procedure [8]—with a control group that did not receive any
treatment after LEEP. The investigators chose vaginal bleeding requir-
ing medical attention as a surrogate for postoperative infection.
Patients were monitored for 3 weeks after the procedure. The study
did not find a significant difference between the groups in terms of
self-reported vaginal bleeding, discharge, lower abdominal pain,
fever, or hospital admission. The study was graded as fair quality be-
cause the number of patients who returned for follow-up was smaller
than the power analysis specified (137 in the treatment group and
153 in the control group). In addition, the control group was not
given a placebo pessary, which alone could confound bleeding or
discharge symptoms.
The overall quality of the evidence regarding antibiotic prophylax-
is for LEEP was graded very low; the quality of evidence for measures
of adverse effects was graded low. The sparseness and the indirect-
ness of the evidence further detracted from the quality. In both stud-
ies, participants were given antibiotics for extended courses after
surgery, which is currently unacceptable by US accreditation stan-
dards for prophylaxis [9]. There was no difference in infection with
antibiotic use, and the adverse effect profile favored placebo.
3.2. Transcervical surgery (hysteroscopic ablation)
Only 1 studymet PICO criteria for transcervical surgery. Bhattacharya
et al. [10] randomized 55 women undergoing hysteroscopic resec-
tion or laser ablation of the endometrium to either amoxicillin/
clavulanate or no antibiotic at induction. The primary outcome
was bacteremia by blood culture but signs of infection were also
reported. The study was stopped early, and thus did not reach
power, after an interim safety analysis found a significant difference
in bacteremia between the groups (2% vs 16%; Pb0.02). However,
there were no differences for clinical outcomes such as fever, pain,
discharge, evaluation by a general practitioner, or treatment with
antibiotics over 2 weeks post-surgery. Based on this sparse evidence,
we suggest not using antibiotic prophylaxis for women undergoing
hysteroscopic endometrial ablation.
3.3. Suction curettage (for products of conception)
Eight randomized trials on antibiotic prophylaxis for first-
trimester suction curettage and 1 randomized trial involving second-
trimesterdilation and evacuation were identified [11–19]. No trials of
dilation and curettage without products of conception met the
inclusion criteria.
3.3.1. Tetracyclines
Five studies investigated tetracycline use [11–15]. In the 3
placebo-controlled studies, the definitions of infection were similar
2525 published abstracts identified (from MEDLINE and Cochrane 
databases: inception to July 16, 2010) 
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Fig. 1. Flow diagram of the selection and systematic review of studies on prophylactic antibiotics for select benign gynecologic surgeries.
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inal pain, tenderness, purulent leukorrhea or vaginal bleeding, leuko-
cytosis, and fever [11–13]. Postoperative follow-up was 2–5 weeks
across the studies. Prieto et al. [11] randomized 345 women to preop-
erative intravenous doxycycline or placebo for first-trimester suction
curettage. Postabortion infection rates were 6.6% for doxycycline and
5.8% for placebo, which was not significantly different. The interven-
tion was not blinded, therefore allowing for bias.
Heisterberg and Gnarpe [12] randomized patients to lymecycline
or placebo for 14 days, starting the morning of surgery. Ninety
women were randomized but only 55 were analyzed because of loss
to follow-up or protocol deviation. Infection rates were 8.3% for anti-
biotics and 22.6% for placebo (P>0.2). The high rate of post-surgical
infection was made more likely because the inclusion criteria re-
quired a history of pelvic inflammatory disease (PID). Limitations in-
cluded small sample size with high loss of participants to follow-up.
The outcome was dependent on participant recall of nonspecific
symptoms, which may have introduced further bias.
Levallois and Rioux [13] had the largest sample size for this proce-
dure, with 1077 women randomized to either doxycycline or placebo.
They tested women for chlamydia cervicitis prior to the procedure
and separately analyzed 1002 women who were negative. A regimen
of 100 mg of oral doxycycline given 1 hour preoperatively and
200 mg administered 30 minutes postoperatively was associated
with a significant reduction in postoperative infection compared
with placebo (from 3% to 0.3%; P=0.001). Participants who received
antibiotics more commonly reported nausea and vomiting.
Two studies compared different doxycycline regimens [14,15].
Lichtenberg and Shott [14] randomized 800 women to doxycycline
for 3 or 7 days after first-trimester suction curettage. There was no
significant difference in infection rates between the regimens but, be-
cause of loss to follow-up, the study did not meet its sample sizerequirement. The other study was a placebo-controlled comparison
of doxycycline taken the night before versus the morning of dilation
and evacuation [15]. This was chiefly an assessment of adverse ef-
fects, and nausea and vomiting were more severe when doxycycline
was taken on the morning of surgery.
3.3.2. Erythromycin
One study investigated the use of oral erythromycin taken twice
daily for 7 days for PID prevention after first-trimester abortion
[16]. The final analysis included 378 women, which met the sample
size requirements for power. Post-surgical PID occurred in 10.5% of
the erythromycin group and 15.9% of the placebo group, which was
not significantly different (P=0.129).
3.3.3. Clindamycin
Larsson et al. [17] performed a multi-institutional study investi-
gating clindamycin vaginal cream after first-trimester abortion. The
study was industry sponsored and the role of the pharmaceutical
manufacturer was unspecified. Patients were instructed to follow-
up if they experienced complications. Of the 1665 patients who
were randomized, 389 (23%) were excluded for reasons such as
loss to follow-up (n=157 [40%]), preoperative chlamydia infection
(n=31 [8%]), and antibiotic treatment outside the protocol (n=72
[19%]). The rate of postoperative infection was 4.5% in the clin-
damycin group and 4.8% in the placebo group (P=0.68).
3.3.4. Ceftriaxone
Henriques et al. [18] performed an RCT of ceftriaxone versus the
“standard of care” for each patient's apparent risk of infection follow-
ing first-trimester termination. Women were categorized as high risk
if they had a history that indicated prior PID or sexually transmitted
infection. Then, in both risk groups, women were randomized to
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was determined based on each patient's assessed risk; low-risk
women were not given any antibiotics, whereas high-risk women
were treated with intravenous ampicillin andmetronidazole preoper-
atively, followed by oral metronidazole and pivampicillin 3 times per
day for 4 days. There was a significant difference in the rates of
post-surgical infection in the low-risk population: 0.7% in the ceftri-
axone group and 3.6% in the no-prophylaxis group (Pb0.05). In the
high-risk population, there was no difference in infection between
those receiving ceftriaxone and those receiving standard of care
(3.7% vs 4.7%; P>0.05). The group of low-risk women who received
ceftriaxone reported a significantly higher rate of diarrhea compared
with controls. All other potential adverse effects were similar between
the groups.
3.3.5. Metronidazole
Heisterberg and Petersen [19] compared metronidazole with pla-
cebo for the prevention of PID following first-trimester elective ter-
mination. Of 119 women randomized, 100 were included in the
analysis; 8 were lost to follow-up, and the remaining cases involved
protocol deviation. Women in the treatment group received 400 mg
of oral metronidazole 1 hour before, then 4 and 8 hours after surger-
y. Women in the placebo group received similarly timed tablets. All
follow-up was completed 2 weeks postoperatively. Rates of infec-
tion were 3.9% in the treatment group and 20.4% in the placebo
group (Pb0.025).
Moderate-quality evidence supports the use of a tetracycline for
infection prophylaxis in first-trimester suction curettage. There is
also moderate- and high-quality evidence to support the use of
ceftriaxone and metronidazole, respectively, to reduce postabortion
infection. Although gastrointestinal adverse effects occur more often
in women receiving prophylaxis, the benefits of reducing post-
procedure infectious morbidity warrant the risk. The optimal regimen
remains unclear because the small number of RCTs used variable reg-
imens for dosage, route, and particular antibiotic. Tetracycline, ceftri-
axone, or metronidazole may be appropriate choices.
3.4. Vaginal surgery (excluding hysterectomy)
Two studies addressing antibiotic prophylaxis in vaginal surgery
met the inclusion criteria [20,21]. Houang et al. [20] performed a
double-blind, randomized, placebo-controlled trial of various gyne-
cologic surgeries, including abdominal surgery without entry into
the vagina (discussed later) and vaginal surgery without entry into
the peritoneal cavity. Participants were randomized to 1 of 3 preop-
erative antibiotic regimens (placebo vs ampicillin–sulbactam vs
ampicillin–metronidazole). Follow-up was 6 weeks. In addition to
pelvic or vaginal infection, the authors attempted to identify UTIs. Infec-
tion rates were not different among the study arms for vaginal surgery
without entry into the peritoneum. Only 30 patients were randomized
and no power analysis was performed, so type II error is a possibility.
Schiøtz and Guttu [21] studied postoperative UTIs and bacteriuria
in 135 women undergoing “vaginal plastic surgery.” Another sub-
group who underwent “routine gynecologic laparotomy” [21] are
discussed later. This was a randomized, double-blind, placebo-
controlled trial but included women who had an indwelling Foley
catheter for 24 hours. The authors observed a benefit of methena-
mine over placebo for UTI prevention when both surgical approaches
were collectively analyzed. However, the subgroup of patients under-
going vaginal surgery (n=55) was not separately analyzed. Eleven
(7.6%) women in the entire study had adverse events: 8 had nausea
(5 methenamine, 3 placebo) and 3 had a rash (1 methenamine, 2
placebo) (P>0.05 for all).
Only 2 trials met PICO criteria for review and it was felt that there
was insufficient information available to guide decision making.3.5. Laparoscopic surgery (excluding hysterectomy)
Two RCTs were identified that evaluated antibiotic use in
benign gynecologic laparoscopic procedures excluding hysterecto-
my [22,23]. Kocak et al. [22] randomized 450 women to either a sin-
gle preoperative dose of a first-generation cephalosporin (n=200)
or no antibiotics (n=250). Indications for surgery included infertil-
ity, endometriosis, tubal ligation, and chronic pelvic pain. The tech-
nique of randomization was not detailed but the percentage of
women listed for each indication was exactly the same in the 2
groups. The physicians caring for the women postoperatively were
not blinded. There were no differences between the groups for
each infectious outcome.
Cormio et al. [23] randomized 356 patients undergoing laparos-
copy to amoxicillin–clavulanate or cefazolin at anesthesia induction.
Surgeries included ovarian cystectomy, myomectomy, adnexectomy,
and endometriosis. One patient in the amoxicillin–clavulanate group
became febrile. The outcomes were not significantly different be-
tween the groups.
In both studies extracted, the rate of infection was low (0%–5.5%),
supporting a minimal need for antibiotics in general. Based on these 2
studies, it was concluded that antibiotic prophylaxis for laparoscopic
surgery does not provide a significant benefit.3.6. Laparotomy (excluding hysterectomy) without entry into vagina
or bowel
Five studies investigating antibiotic prophylaxis in abdominal gy-
necologic surgeries excluding hysterectomy [20,21,24–26] met the
present PICO criteria. The largest and highest-quality study reported
a benefit of perioperative antibiotics; in this 3-armed, double-blind,
placebo-controlled trial [24], 1350 women undergoing mini-
laparotomy tubal ligation were randomized to tetracycline, ampicil-
lin, or placebo for 5 days postoperatively. Participants were assessed
2 and 7 days after surgery for infection (defined as temperature
higher than 100.4 °F) or signs of inflammation (erythema, discharge,
pain, swelling, or dehiscence). There was a significantly lower inci-
dence of infection with tetracycline than with placebo (1.8% vs 5.8%;
P=0.025). There was no significant difference in infection rates be-
tween ampicillin and placebo, or ampicillin and tetracycline.
Two studies found no difference in infection rates between groups
receiving antibiotics and those receiving placebo. In the study by
Houang et al. [20], for abdominal surgery without entry into the vagi-
na, 79 women were randomized to sulbactam–ampicillin, metronida-
zole–ampicillin, or placebo. The authors found no difference in fever
or wound infection between the groups. “No significant side effect”
was seen but adverse events were not otherwise described. Bhatia
et al. [25] performed a small quasi-randomized (assignment was
based on hospital number) study of 26 women undergoing retropubic
urethropexy. Three of 12 patients who did not receive antibiotics de-
veloped wound abscesses, whereas no abscesses developed among
the patients who received cefazolin. Statistical analysis of infection
rates was not reported. The authors also reported a “fever index” cal-
culation [27], which was significantly different between the groups
but is of unclear clinical utility.
Periti et al. [26] compared 2 cephalosporins. The authors random-
ized women undergoing cesarean delivery, abdominal or vaginal
hysterectomy, or myomectomy via exploratory laparotomy. The
present review included only the 36 myomectomy patients, whose
results were reported separately. Although this was a small subset
of patients, no significant difference in infection rates was seen be-
tween women treated with cefazolin and those who received
cefotaxime. In their methenamine trial, Schiøtz et al. [21] reported
a significantly lower rate of UTIs and asymptomatic bacteriuria in
the study population.
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The study by Akhter et al. [24] was remarkable because of its sound
study design and large sample size but the procedure performed is
only questionably generalizable to other, more extensive surgeries.
Adverse events were described in only 1 study, in which no difference
was observed between the study and the control populations. The
evidence indicates that there is a benefit to using perioperative
antibiotics for women undergoing abdominal gynecologic surgery
excluding hysterectomy without entry into the vagina or bowel.
4. Discussion
Optimization of surgical outcomes is a priority for physicians, pa-
tients, medical institutions, and accrediting bodies. Despite the widely
accepted practice of antibiotic prophylaxis for surgery, the few RCTs
identified in the present systematic review on antibiotic prophylaxis
for non-hysterectomy gynecologic procedures highlight low-quality
evidence for many practices. In some cases, such as vaginal surgery,
the data were too weak to provide a clear answer. Newer procedures
also lack data. It is a common finding that accepted practices may
still merit re-examination and further study.
In 2009, ACOG published clinical guidelines regarding prophylac-
tic antibiotics for gynecologic surgery [1]. The guidelines are compre-
hensive in their coverage of the wide range of gynecologic procedures
that exist. Although the guidelines can be extremely helpful to gyne-
cologic surgeons, they incorporate a range of study designs, include
studies from other fields, and are based on group consensus and ex-
pert opinion [1]. The aim of the present paper was to critically evalu-
ate the evidence regarding benign gynecologic surgeries using a
pre-established PICO for study inclusion. In contrast to the variety of
studies referenced in the ACOG guidelines, the present review includ-
ed only RCTs of gynecology-specific surgical procedures. We believe
that it is informative and relevant to gynecologic surgeons to know
that the existing evidence regarding prophylactic antibiotic use for
the majority of gynecologic procedures remains poor. Only 19 studies
meeting the inclusion criteria for the 6 routes of gynecologic surgery
were identified, of which 3 are also cited in the ACOG guidelines.
Careful review of the 55 references cited by ACOG showed no further
high-quality studies (n=16) that would have met the criteria be-
cause these remaining Level I studies examined other procedures
such as intrauterine device placement or were from other fields
such as colorectal surgery [1].
Given the paucity of high-quality evidence from studies on gyne-
cologic surgery, evidence from similar fields and procedures may be
extrapolated to fill these gaps. For example, studies from colorectal
surgery, general surgery, and urologic surgery offer some applicability
to gynecologic pelvic surgery. As a field, it may be wise to consider
whether this practice should be temporary or whether studies specif-
ic to women undergoing these procedures should be carried out to
provide best guidance. Early adaptation in gynecology of procedures
considered substantially equivalent to those in other fields has
previously led to concerns for patient safety [28]. Lesser-studied
procedures and those unique to gynecology, such as advanced laparo-
scopic or robotic surgery in women and mesh placement in prolapse
surgery, still merit consideration for study, given the lack of data
found for these surgeries.
The strengths of the present study were the systematic review
techniques used in a group with methods and domain experience
[29,30], and the lack of conflicts of interest. A comprehensive and de-
tailed search of relevant published RCTs was used to collect the data,
and the review was limited to gynecology studies. Multiple experi-
enced gynecologic surgeons assessed the studies, and group consen-
sus was used to assure uniformity.
There were limitations to the present study. As with any systemat-
ic review, the information collected was shaped by the available
evidence, which may reflect publication bias. There was a limitednumber of RCTs for most surgeries, and they were mostly of poor
quality. Insufficient evidence precluded a clear answer for vaginal
surgery. The results were influenced by lack of consistency in the def-
inition of infection between studies, and the timing and delivery of
“prophylaxis” were also variable. Several studies used prolonged
postoperative courses of medication, which would not be categorized
as prophylaxis using current US standards. There was limited oppor-
tunity to discuss the best choice of antibiotic because few studies
compared antibiotics, and some studies used medications not cur-
rently available in the USA. Questions also arose about the applicabil-
ity of studies that were published some time ago because certain
practices are now obsolete, such as prolonged hospitalization after
short laparoscopic procedures. Practice variations between different
countries may also limit the relevance of the results. Notably, the
study was also limited with regard to the type of surgery per-
formed, including advanced laparoscopic procedures and pelvic re-
construction surgery involving the use of graft material, because no
RCTs examining perioperative antibiotics in these surgeries were
identified.
In conclusion, the present systematic review summarizes the
highest-quality evidence available in the English-language gynecolo-
gy literature on antibiotic prophylaxis. We expect that the informa-
tion presented can be used to inform future research and providers
seeking to give best care to their patients. We recommend further
clinical studies on prophylactic antibiotics for procedures such as vag-
inal surgery without hysterectomy, advanced laparoscopic and robot-
ic surgery, and surgery involving grafts.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.ijgo.2012.06.023.
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